Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 2
1955 5
1956 3
1957 5
1958 6
1959 9
1960 5
1961 7
1962 7
1963 24
1964 21
1965 15
1966 24
1967 33
1968 25
1969 29
1970 18
1971 20
1972 29
1973 36
1974 40
1975 26
1976 28
1977 27
1978 19
1979 20
1980 19
1981 27
1982 14
1983 23
1984 14
1985 17
1986 14
1987 11
1988 10
1989 10
1990 4
1991 8
1992 17
1993 11
1994 10
1995 6
1996 19
1997 50
1998 57
1999 61
2000 45
2001 25
2002 26
2003 20
2004 10
2005 19
2006 24
2007 13
2008 12
2009 15
2010 25
2011 33
2012 47
2013 62
2014 63
2015 41
2016 49
2017 44
2018 42
2019 42
2020 45
2021 49
2022 57
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,616 results
Results by year
Filters applied: . Clear all
Page 1
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Son JW, Kim S. Son JW, et al. Diabetes Metab J. 2020 Dec;44(6):802-818. doi: 10.4093/dmj.2020.0258. Epub 2020 Dec 23. Diabetes Metab J. 2020. PMID: 33389955 Free PMC article. Review.
Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) can be used long-term (>12 weeks) to promote weight loss by suppressing appetite or decreasing fat absorption. ...
Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liragl …
Pharmacotherapy for obesity: What you need to know.
Bersoux S, Byun TH, Chaliki SS, Poole KG. Bersoux S, et al. Cleve Clin J Med. 2017 Dec;84(12):951-958. doi: 10.3949/ccjm.84a.16094. Cleve Clin J Med. 2017. PMID: 29244650 Free article. Review.
Phentermine/topiramate for the treatment of obesity.
Smith SM, Meyer M, Trinkley KE. Smith SM, et al. Ann Pharmacother. 2013 Mar;47(3):340-9. doi: 10.1345/aph.1R501. Ann Pharmacother. 2013. PMID: 23482732 Review.
OBJECTIVE: To review the pharmacology, efficacy, and safety of phentermine/topiramate (PHEN/TPM) in the management of obese patients. DATA SOURCES: MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine …
OBJECTIVE: To review the pharmacology, efficacy, and safety of phentermine/topiramate (PHEN/TPM) in the management of obese patients. …
Drugs for Treating Obesity.
Ryan DH. Ryan DH. Handb Exp Pharmacol. 2022;274:387-414. doi: 10.1007/164_2021_560. Handb Exp Pharmacol. 2022. PMID: 34783910
Older medications approved for chronic weight management (orlistat, naltrexone/bupropion, liraglutide 3 mg and, in the USA, phentermine/topiramate) have not been widely adopted by health care providers. ...
Older medications approved for chronic weight management (orlistat, naltrexone/bupropion, liraglutide 3 mg and, in the USA, phentermine …
Obesity: Pharmacotherapy.
Powell A. Powell A. FP Essent. 2020 May;492:25-29. FP Essent. 2020. PMID: 32383845
Currently, five drugs are approved for weight management in adults: phentermine, orlistat, phentermine-topiramate, bupropion-naltrexone, and liraglutide. ...
Currently, five drugs are approved for weight management in adults: phentermine, orlistat, phentermine-topiramate, bupropion-n …
Obesity Therapy: How and Why?
Paccosi S, Cresci B, Pala L, Rotella CM, Parenti A. Paccosi S, et al. Curr Med Chem. 2020;27(2):174-186. doi: 10.2174/0929867326666190124121725. Curr Med Chem. 2020. PMID: 30678612
RESULTS: Anti-obesity drugs with central mechanisms, such as phentermine and lorcaserin, are available in USA, but not in Europe. Phentermine/topiramate and naltrexone/bupropion combinations are now available, even though the former is still under investigation from …
RESULTS: Anti-obesity drugs with central mechanisms, such as phentermine and lorcaserin, are available in USA, but not in Europe. …
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Allison DB, et al. Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3. Obesity (Silver Spring). 2012. PMID: 22051941 Free PMC article. Clinical Trial.
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. ...
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine …
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Garvey WT, et al. Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7. Am J Clin Nutr. 2012. PMID: 22158731 Free PMC article. Clinical Trial.
BACKGROUND: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with 2 w …
BACKGROUND: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle …
A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T. Safer DL, et al. Int J Eat Disord. 2020 Feb;53(2):266-277. doi: 10.1002/eat.23192. Epub 2019 Nov 13. Int J Eat Disord. 2020. PMID: 31721257 Clinical Trial.
OBJECTIVE: Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has utility for binge eating. ...
OBJECTIVE: Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has …
[Phentermine--a "weighty" or a dangerous substance?].
Skopp G, Jantos R. Skopp G, et al. Arch Kriminol. 2013 Mar-Apr;231(3-4):116-29. Arch Kriminol. 2013. PMID: 23678625 Review. German.
Phentermine is an isomer of methamphetamine though is not optically active such as e. g. amphetamine. ...Due to its declining effect with time and its addiction potential it has been recommended that phentermine should be used for a few weeks only. Phentermine …
Phentermine is an isomer of methamphetamine though is not optically active such as e. g. amphetamine. ...Due to its declining effect …
1,616 results